Immutep (ASX:IMM) - CEO, Marc Voigt
CEO, Marc Voigt
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Immutep (IMM) has successfully completed a $12 million placement
  • Approximately 96 million ordinary shares were issued to professional, sophisticated and institutional investors at a price of 12.5 cents each
  • The shares are expected to settle on May 4 and be issued on May 5
  • The company will use the money to drive the development of its clinical programs, research and development, and general working capital
  • Immutep is down a slight 2.86 per cent and shares are currently trading for 17 cents each

Biotech company Immutep (IMM) has successfully completed a $12 million placement.

Approximately 96 million ordinary shares were issued to professional, sophisticated and institutional investors at a price of 12.5 cents each.

That price represents a 15.5 per cent discount to the volume weighted average price (VWAP) from the 15 days up to, and including, April 24.

The shares are expected to settle on May 4 and be issued on May 5.

Immutep will use the money to fund its LAG-3 clinical program in autoimmune disease and immune-oncology.

This includes financing its eftilagimod alpha (efti) anti-cancer drug, the development of IMP761, research and development, and general corporate and manufacturing purposes.

“The support received for this financing from high quality new and existing investors demonstrates strong confidence in Immutep’s clinical program,” CEO Marc Voigt commented.

“This financing provides certainty of funding for Immutep and I would like to thank existing shareholders for their continued support and welcome new investors to the register,” he said.

Efti

Efti, also known as IMP321, is Immutep’s anti-cancer drug which is designed to treat metastatic breast cancer.

In late March, the company reported on data from a breast cancer trial.

In the trial, Immutep treated 227 metastatic breast cancer patients with efti and paclitaxel (anti-cancer chemotherapy drug and chemotherapy medication) to boost the T-cell immune response against tumours.

In the body, T-cells play a major role in defending the body against viruses, bacteria and parasites, and those with a low T-cell count generally have a harder time fighting infections.

Results showed that at the six-month mark, progression-free survival was favourable to efti over a placebo.

Of the patients who received efti and paclitaxel, 63 per cent were progression-free, which is higher than the 54 per cent who received placebo.

IMP761

IMP761 is an immunosuppressive agonist antibody to LAG-3, meaning it attaches itself to the LAG-3 receptor on activated T-cells.

The LAG-3 receptor subdues the T-cell activation and ensures a state of immune balance.

By binding to the receptor, the agonist antibody inhibits the T-cell’s increased reaction against the body’s own tissue.

By doing this, it is believed that IMP761 reduces the excessive immune reaction associated with autoimmune diseases by addressing the cause rather than the inflammation.

Immutep is down a slight 2.86 per cent and shares are trading for 17 cents each at 11:29 am AEST.

IMM by the numbers
More From The Market Herald

" Lumos Diagnostics (ASX:LDX) withdraws from RAT manufacturing facility project with VIC government

Lumos Diagnostics (ASX:LDX) has backed out of its deal with the Victorian Government to establish a…

" Imugene (ASX:IMU) sees “positive signs” from lung cancer trial, presents data at 2022 world conference

Imugene (ASX:IMU) presents new data from its PD1-Vaxx trial in non-small cell lung cancer patients at…

" Creso Pharma’s (ASX:CPH) Mernova lands new purchase orders

Creso Pharma's (ASX:CPH) Canadian subsidiary, Mernova medicinal secured new purchase orders last month.
The Market Herald Video

" Neuren Pharmaceuticals (ASXL:NEU) launches phase two trials of NNZ-2591

Neuren Pharmaceuticals (ASX:NEU) opens enrolment for phase two clinical trials of its drug candidate NNZ-2591.